VALacyclovir In Delaying Antiretroviral Treatment Entry.

Trial Profile

VALacyclovir In Delaying Antiretroviral Treatment Entry.

Phase of Trial: Phase III

Latest Information Update: 08 Mar 2018

At a glance

  • Drugs Valaciclovir (Primary)
  • Indications Herpes simplex virus type 2 infections; HIV infections; HIV-1 infections
  • Focus Biomarker; Therapeutic Use
  • Acronyms VALIDATE
  • Most Recent Events

    • 02 Mar 2018 Status changed from active, no longer recruiting to completed.
    • 10 Jun 2017 Biomarkers information updated
    • 02 Jun 2017 Planned End Date changed from 1 Sep 2017 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top